Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963611 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT01963611 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 255 participants.
The verdict
NCT01963611, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duration of 40 weeks.
Interventions
- DRUG Plovamer acetate 0.5 milligram (mg)
- DRUG Copaxone 20 mg
- DRUG Plovamer acetate 3 mg
- DRUG Plovamer acetate 10 mg
- DRUG Plovamer acetate 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963611
The ClinicalTrials.gov registry entry for NCT01963611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Plovamer acetate 0.5 milligram (mg) is the first listed.
NCT01963611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01963611 about?
NCT01963611 is a clinical study titled "Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)". This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duratio...
What is the current status of trial NCT01963611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2013-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01963611?
The interventions under investigation include: Plovamer acetate 0.5 milligram (mg) (DRUG), Copaxone 20 mg (DRUG), Plovamer acetate 3 mg (DRUG), Plovamer acetate 10 mg (DRUG), Plovamer acetate 20 mg (DRUG).
Who is sponsoring clinical trial NCT01963611?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.